Clinical trials in melanoma patients with brain metastases

Pigment Cell and Melanoma Research

Volumn 28, Issue 6, 2015, Pages 741-743

  Yushak, Melinda L ^a   Chiang, Veronica L ^a   Kluger, Harriet M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; FOTEMUSTINE; IPILIMUMAB; SORAFENIB; TEMOZOLOMIDE; VEMURAFENIB;

BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; HUMAN; LETTER; LOCAL THERAPY; METASTATIC MELANOMA; SYSTEMIC THERAPY; BRAIN NEOPLASMS; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MELANOMA; TREATMENT OUTCOME;

EID: 84944452798     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12401     Document Type: Letter

References (13)

1. Amaravadi, R.K., Schuchter, L.M., McDermott, D.F. et al. (2009). Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res. 15, 7711-7718.
2. Bachelot, T., Cropet, C., Dieras, V., Jimenez, M., and Campone, M. (2013). Brain metastases from HER2-positive breast cancer - authors' reply. Lancet Oncol. 14, e3-e4.
3. Costa, D.B., and Kobayashi, S. (2012). Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. J. Thorac. Oncol. 7, 623-625.
4. Dummer, R., Goldinger, S.M., Turtschi, C.P., Eggmann, N.B., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P.R., Felderer, L., and Rinderknecht, J.D. (2014). Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur. J. Cancer 50, 611-621.
5. Falchook, G.S., Long, G.V., Kurzrock, R. et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
6. Flanigan, J.C., Jilaveanu, L.B., Faries, M., Sznol, M., Ariyan, S., Yu, J.B., Knisely, J.P., Chiang, V.L., and Kluger, H.M. (2011). Melanoma brain metastases: is it time to reassess the bias? Curr. Probl. Cancer 35, 200-210.
7. Flanigan, J.C., Jilaveanu, L.B., Chiang, V.L., and Kluger, H.M. (2013). Advances in therapy for melanoma brain metastases. Clin. Dermatol. 31, 264-281.
8. di Giacomo, A.M., Ascierto, P.A., Pilla, L. et al. (2012). Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879-886.
9. Gibney, G. T., Gauthier, G., Ayas, C., Galebach, P., Wu, E. Q., Abhyankar, S., Reyes, C., Guerin, A., and Yim, Y.M. (2015). Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Cancer Med. doi: 10.1002/cam4.475 [Epub ahead of print].
10. Knisely, J.P., Yu, J.B., Flanigan, J., Sznol, M., Kluger, H.M., and Chiang, V.L. (2012). Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117, 227-233.
11. Long, G.V., Trefzer, U., Davies, M.A. et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
12. Margolin, K., Ernstoff, M.S., Hamid, O. et al. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465.
13. Weber, J.S., Amin, A., Minor, D., Siegel, J., Berman, D., and O'Day, S.J. (2011). Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 21, 530-534.